SecBot SecBot
8-K ·Filed May 6, 2026

RPRX

Royalty Pharma plc
BULLISH
Impact 6/10
Horizonweeks Processed6mo ago SEC0001802768-26-000008
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The raised guidance and double-digit Royalty Receipts growth signal continued momentum in the core royalty portfolio. Watch for further R&D co-funding deals (J&J, Teva) and clinical catalysts (daraxonrasib pancreatic cancer data, Ziihera PDUFA date Aug 25, 2026) that could drive incremental upside to Portfolio Receipts.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$50.72
T+0 close · May 6, 2026 · via day close
Latest settled
+15.20%
T+60 · $58.43
Vs SPY
+13.14%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 6 $50.72entry
  2. T+1 · 6mo ago −1.03%α −0.69% · $50.20
  3. T+5 · 6mo ago +1.93%α +0.80% · $51.70
  4. T+20 · 6mo ago +8.38%α +5.60% · $54.97
  5. T+60 · 4mo ago +15.20%α +13.14% · $58.43

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Royalty Pharma reported Q1 2026 Portfolio Receipts of $925M (+10% YoY) and Royalty Receipts of $887M (+13% YoY), driven by Tremfya, Voranigo, and Evrysdi. The company raised full-year 2026 Portfolio Receipts guidance to $3.325B-$3.450B (from $3.275B-$3.425B), reflecting expected Royalty Receipts growth of 4%-8%. Net cash from operations was $718M, up 20% YoY, and the company deployed $528M in capital during the quarter.

Key Financial Metrics

EPS
$1.30
est $1.18 · +10.2%
Revenue
$925.0M
est $874.1M · +5.8% · +10.0% YoY
Rating
beat
Guidance
$3.325B-$3.450B
raised

Key Facts

  • Portfolio Receipts grew 10% YoY to $925M in Q1 2026
  • Royalty Receipts grew 13% YoY to $887M
  • Raised full-year 2026 Portfolio Receipts guidance to $3.325B-$3.450M (from $3.275B-$3.425B)
  • Net cash from operations of $718M, up 20% YoY
  • Adjusted EBITDA (non-GAAP) of $889M, up 21% YoY
  • Portfolio Cash Flow (non-GAAP) of $722M, up 18% YoY
  • Announced up to $1.25B in new royalty transactions in Q1
  • Recorded $69M non-cash impairment charge related to Tazverik
  • Repurchased 1.1M shares for $50M in Q1

Financial Impact

Portfolio Receipts guidance raised by $50M at midpoint; Royalty Receipts growth of 4-8% expected for FY2026

Portfolio ReceiptsRoyalty ReceiptsAdjusted EBITDAPortfolio Cash Flowoperating cash flow

Risk Factors

  • Promacta revenue declined 61% YoY due to generic competition
  • Tazverik withdrawal and $69M impairment charge
  • Potential for further generic erosion in the portfolio
  • Interest expense increased to $94M from $65M YoY

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001802768-26-000008
Document: 0001802768-26-000008-index.html0001802768-26-000008
Document: 0001802768-26-000008.txt0001802768-26-000008
8-K Data (Synthetic)0001802768-26-000008

Track record

23 reports on RPRX

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +12.99% at T+60 after the Aug 5, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry price pending
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $67.57 to $68.97 Now $68.53 +1.41% ▲ +2.07% −1.22% vs SPY
  3. Nov 4, 202612d ago 8-K Neutral 5/10 No price data
  4. Nov 4, 202612d ago Press Release Bullish 6/10 Entry $67.56 to $70.01 Now $68.53 +1.43% ▲ +3.63% +4.54% vs SPY
  5. Sep 30, 20266w ago Insider Cluster Bearish 5/10 Entry $57.63 to $56.21 Now $68.53 −18.91% ▲ +2.46% +3.77% vs SPY
  6. Sep 4, 202610w ago Press Release Bearish 5/10 Entry $60.59 to $58.47 Now $68.53 −13.10% ▲ +3.50% +2.38% vs SPY
  7. Aug 19, 202612w ago Insider Cluster Neutral 3/10 Entry $60.57 to $61.92 Now $68.53 +13.14% ▲ +2.24% +1.12% vs SPY
  8. Aug 12, 202613w ago 144 Neutral 3/10 Entry $58.56 to $60.58 Now $68.53 +17.02% ▲ +3.45% +5.41% vs SPY
  9. Aug 5, 202614w ago 8-K Bullish 6/10 Entry $57.75 to $59.22 Now $68.53 +18.66% ▲ +2.55% +2.19% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Neutral 2/10 Entry $57.77 to $57.96 Now $68.53 +18.62% ▲ +0.33% −0.60% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (11h 42m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026